Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Allocetra in TMJ-OA
NCT06748651Phase 1Recruiting
- Start
- Dec 2024
- Primary completion
- Feb 2026
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Allocetra in temporomandibular joint osteoarthritis. Primary endpoint: Adverse Events at 12 months. Started Dec 2024; status: recruiting.
02
Drugs
Allocetra
03
Conditions
temporomandibular joint osteoarthritis
Beyond the preview
Go deeper on NCT06748651.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06748651.